A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy

J. R. Lange, A. A. Raubitschek, Barbara A Pockaj, W. F. Spencer, M. T. Lotze, S. L. Topalian, J. C. Yang, S. A. Rosenberg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A clinical trial was undertaken to evaluate the feasibility of combining radiation therapy and immunotherapy. Twenty-eight patients with metastatic cancer were treated with rapid fractionation radiation up to 2,000 cGy, followed within 24 h by a course of interleukin 2 (IL-2) at 720,000 IU/kg or tumor-infiltrating lymphocytes (TILs) and IL-2 at 720,000 IU/kg. All patients tolerated treatment without any apparent increase in toxicity referable to the irradiation. Four patients had significant shrinkage of tumor at the irradiated site. Only two patients showed significant tumor shrinkage both inside and outside of the irradiated field. While rapid fractionation radiation can be safely administered in combination with immunotherapy, we observed no apparent synergy in antitumor effect in this small number of patients.

Original languageEnglish (US)
Pages (from-to)265-271
Number of pages7
JournalJournal of Immunotherapy
Volume12
Issue number4
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Immunotherapy
Interleukin-2
Radiotherapy
Radiation
Tumor-Infiltrating Lymphocytes
Neoplasms
Clinical Trials
Therapeutics

Keywords

  • Immunotherapy
  • Interleukin-2
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Lange, J. R., Raubitschek, A. A., Pockaj, B. A., Spencer, W. F., Lotze, M. T., Topalian, S. L., ... Rosenberg, S. A. (1992). A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. Journal of Immunotherapy, 12(4), 265-271. https://doi.org/10.1097/00002371-199211000-00007

A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. / Lange, J. R.; Raubitschek, A. A.; Pockaj, Barbara A; Spencer, W. F.; Lotze, M. T.; Topalian, S. L.; Yang, J. C.; Rosenberg, S. A.

In: Journal of Immunotherapy, Vol. 12, No. 4, 1992, p. 265-271.

Research output: Contribution to journalArticle

Lange, JR, Raubitschek, AA, Pockaj, BA, Spencer, WF, Lotze, MT, Topalian, SL, Yang, JC & Rosenberg, SA 1992, 'A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy', Journal of Immunotherapy, vol. 12, no. 4, pp. 265-271. https://doi.org/10.1097/00002371-199211000-00007
Lange, J. R. ; Raubitschek, A. A. ; Pockaj, Barbara A ; Spencer, W. F. ; Lotze, M. T. ; Topalian, S. L. ; Yang, J. C. ; Rosenberg, S. A. / A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. In: Journal of Immunotherapy. 1992 ; Vol. 12, No. 4. pp. 265-271.
@article{05c14cd4b187415397fe216d9a9b7fb3,
title = "A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy",
abstract = "A clinical trial was undertaken to evaluate the feasibility of combining radiation therapy and immunotherapy. Twenty-eight patients with metastatic cancer were treated with rapid fractionation radiation up to 2,000 cGy, followed within 24 h by a course of interleukin 2 (IL-2) at 720,000 IU/kg or tumor-infiltrating lymphocytes (TILs) and IL-2 at 720,000 IU/kg. All patients tolerated treatment without any apparent increase in toxicity referable to the irradiation. Four patients had significant shrinkage of tumor at the irradiated site. Only two patients showed significant tumor shrinkage both inside and outside of the irradiated field. While rapid fractionation radiation can be safely administered in combination with immunotherapy, we observed no apparent synergy in antitumor effect in this small number of patients.",
keywords = "Immunotherapy, Interleukin-2, Radiation therapy",
author = "Lange, {J. R.} and Raubitschek, {A. A.} and Pockaj, {Barbara A} and Spencer, {W. F.} and Lotze, {M. T.} and Topalian, {S. L.} and Yang, {J. C.} and Rosenberg, {S. A.}",
year = "1992",
doi = "10.1097/00002371-199211000-00007",
language = "English (US)",
volume = "12",
pages = "265--271",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy

AU - Lange, J. R.

AU - Raubitschek, A. A.

AU - Pockaj, Barbara A

AU - Spencer, W. F.

AU - Lotze, M. T.

AU - Topalian, S. L.

AU - Yang, J. C.

AU - Rosenberg, S. A.

PY - 1992

Y1 - 1992

N2 - A clinical trial was undertaken to evaluate the feasibility of combining radiation therapy and immunotherapy. Twenty-eight patients with metastatic cancer were treated with rapid fractionation radiation up to 2,000 cGy, followed within 24 h by a course of interleukin 2 (IL-2) at 720,000 IU/kg or tumor-infiltrating lymphocytes (TILs) and IL-2 at 720,000 IU/kg. All patients tolerated treatment without any apparent increase in toxicity referable to the irradiation. Four patients had significant shrinkage of tumor at the irradiated site. Only two patients showed significant tumor shrinkage both inside and outside of the irradiated field. While rapid fractionation radiation can be safely administered in combination with immunotherapy, we observed no apparent synergy in antitumor effect in this small number of patients.

AB - A clinical trial was undertaken to evaluate the feasibility of combining radiation therapy and immunotherapy. Twenty-eight patients with metastatic cancer were treated with rapid fractionation radiation up to 2,000 cGy, followed within 24 h by a course of interleukin 2 (IL-2) at 720,000 IU/kg or tumor-infiltrating lymphocytes (TILs) and IL-2 at 720,000 IU/kg. All patients tolerated treatment without any apparent increase in toxicity referable to the irradiation. Four patients had significant shrinkage of tumor at the irradiated site. Only two patients showed significant tumor shrinkage both inside and outside of the irradiated field. While rapid fractionation radiation can be safely administered in combination with immunotherapy, we observed no apparent synergy in antitumor effect in this small number of patients.

KW - Immunotherapy

KW - Interleukin-2

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0026706080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026706080&partnerID=8YFLogxK

U2 - 10.1097/00002371-199211000-00007

DO - 10.1097/00002371-199211000-00007

M3 - Article

C2 - 1477077

AN - SCOPUS:0026706080

VL - 12

SP - 265

EP - 271

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 4

ER -